Previous 10 | Next 10 |
VANCOUVER, British Columbia , Feb. 19, 2019 /PRNewswire/ -- Weekend Unlimited Inc. ("Weekend" or the "Company") (CSE: POT ) (FSE: 0OS1) (OTCMKTS: WKULF) is pleased to announce that Northern Lights Supply in Nisku, Alberta has received its initial shipment from AGLC allowing...
Premier Health Provides Corporate Update Canada NewsWire VANCOUVER, British Columbia, Feb. 14, 2019 VANCOUVER, British Columbia , Feb. 14, 2019 /CNW/ -- Premier Health Group (CSE: PHGI) (OTCQB: PHGRF) ( Frankfurt : 6PH) (the "Company" or "Premier Health"), a Company focus...
Atossa Genetics (NASDAQ: ATOS ) +29% on updating the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. More news on: Atossa Genetics, ...
February 7, 2019 Palm Beach, FL – (February 5, 2018) – The biotech drug industry, with encouragement from the Food and Drug Administration (FDA), is advancing efforts to modernize clinical trials, streamlining the process of figuring out whether a treatment actually works.&...
MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona (“CTCL”), a rare and deadly skin cancer HOUSTON, Feb. 07, 201...
The FDA has granted Orphan Drug status to Moleculin Biotech's (NASDAQ: MBRX ) WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. Unlike other indu...
HOUSTON, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System...
NEW YORK, Dec. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON), Henry Schein, Inc. (NASDAQ:HSIC), Arg...
SELLAS Life Sciences (NASDAQ: SLS ) +20% on positive analyst action . More news on: SELLAS Life Sciences Group, Inc., Attunity Ltd, Floor & Decor Holdings, Inc., Stocks on the move, , Top stock market news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $109.21 on volume of 508,402,989 shares Redhill Biopharma Ltd. (RDHL) rose 97.9% to $0.76 on volume of 355,380,053 shares PROSHARES TRUST (SQQQ) rose 7.3% to $9.22 on volume of 284,777,109 shares ...
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...